PharmAla Biotech is pleased to announce the appointment of Dr. Harriet de Wit to its Board of Directors. Dr. de Wit is a well known researcher of MDMA and other psychedelic molecules, serving as Professor of Psychiatry and Behavioural Neuroscience at the University of Chicago.

“I’m very pleased to join the Board of Directors of PharmAla Biotech. Having worked with the company in an informal capacity for a few months, I’m thrilled at the opportunity to now be able to help steer the company forward. There are great opportunities for clinical development of MDMA and the MDXX class – and PharmAla is one of the few companies looking to develop novel approaches in this space,” said Dr. de Wit.

Prof. de Wit will bring crucial expertise in psychiatry and psychopharmacology to PharmAla’s board, as well as a wide network within the scientific community developed over years of experience.

“Harriet has already brought so much value to the company, “said Nicholas Kadysh, CEO of PharmAla. “I’m looking forward to a long and very fruitful collaboration.”

PharmAla Biotech is a Canadian Psychedelics company focused on the development and manufacturing of MDMA and the MDXX class of molecules. In a relatively short time, the company has begun process development for MDMA and filed several provisional patents for the development of novel formulations of MDMA and MDXX class molecules.

“As Board Chair of PharmAla Biotech, I’m focused on finding the best possible candidates to represent the company and its investors, “stated Jodi Butts. “Harriet will not only help accomplish the company’s research and development goals, but will be a strong voice in the boardroom.”

Contact: Nicholas Kadysh, CEO